Efficacy and safety of camrelizumab plus apatinib in advanced urachal cancer (RUN-SC-0102): a single-arm, multicentre, phase 2 trial in ChinaResearch in context

Summary: Background: Urachal carcinoma (UrC) constitutes a rare and biologically distinct adenocarcinoma for which no standardised therapeutic regimen currently exists. We aimed to evaluate the efficacy and safety of combined therapy with camrelizumab, a humanised monoclonal anti programmed death-1...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Mengyang Ju, Wenfeng Li, Linjun Hu, Xiongjun Ye, Wangjun Yan, Sheng Zhang
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2026-06-01
Rangatū:	EClinicalMedicine
Ngā marau:	Urachal cancer Camrelizumab Apatinib PD-1 inhibitor VEGFR inhibitor Clinical trial
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S2589537026002269
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!